Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
Simon Leung, Partner of Baker McKenzie, and Terry Xu, Senior Counsel at FenXun Partners, examine key regulatory shifts in 2024 and provide an outlook of potential regulatory trends for the banking and finance sector in 2025
Chinese EV maker Geely expands into Brazil through a partnership with France’s Renault; The parent company of Calvin Klein and Tommy Hilfiger is blacklisted by China; and Canadian Solar is sued by China’s Trina Solar over patent infringement.
China Law & Practice Awards 2024 sees a broad spectrum of law firms seize crown in individual practices. Fangda Partners and Clifford Chance win top accolades in the 18th annual CLP Awards.
China increases regulatory framework for the pharma and life sciences sectors; Chinese authorities intervene to regulate VC funds management; and internet content providers could face stricter scrutiny on military-related content.
In 2024, significant progress was made in the fields of legislation, merger control, administrative enforcement, and litigation under the PRC Anti-Monopoly Law. Huang Wei, Gao Chang, Zhu Fan and Ren Yuying of Tian Yuan Law Firm set out an overview of the major developments and key takeaways
The sudden rise of DeepSeek AI has prompted regulators’ concerns over its processing of data; the EU plans to ensure e-commerce platforms are compliant with its laws; and U.S.-China tensions are pushing China-focused private equity funds to expand beyond China.